Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

JP Morgan raises target price on Trustpilot

(Sharecast News) - Analysts at JP Morgan raised their target price on review website operator Trustpilot from 190.0p to 250.0p on Tuesday, stating earnings momentum looked set to continue as the group transitions into a fast-growing free cashflow generator. JP Morgan stated that since it upgraded Trustpilot to 'overweight' from 'neutral' in February 2023, guidance has been upgraded four times, driving earnings and FCF estimates upward.

"Shares are up ~125% in the last six months and investors we interact with are increasingly focussed on where incremental upside comes from," noted JPM.

The broker reexamined its investment thesis on Trustpilot and took "a refreshed view" on what drives performance from here.

"Looking forward, we see earnings supported by: 1) Further operational leverage to come, driving continued momentum in earnings upgrades; 2) Manageable top-line estimates through 2024; 3) Conservative FCF consensus outlook through 2024, supported by Trustpilot's negative working capital profile; 4) Trustpilot well positioned as a GenAI winner," said JPM.

It also stated it sees valuation support from Trustpilot's ongoing share buyback programme, as well as a continued beat and raise cadence under new management, with a focus on profitable growth, and a supportive bond yield environment.

"We increase our underlying EBITDA estimates ~13-16% and raise our PT to 250p, continuing to see Trustpilot as a unique asset well positioned for multi-year profitable growth (JPMe ~54% FCF CAGR 2023-2026)," concluded JPM.

Reporting by Iain Gilbert at Sharecast.com

Share this article

Related Sharecast Articles

Sirius Real Estate ups dividend as profits jump 32%
(Sharecast News) - Profits at business and industrial parks developer Sirius Real Estate surged by nearly a third in the year ended 31 March, helping the company to increase dividends for the tenth straight year.
GSK to appeal Delaware ruling on jury trials in Zantac cancer cases
(Sharecast News) - Pharma giant GSK said it would be appealing against a US court decision allowing jury trials in cases brought by cancer sufferers claiming its heartburn drug caused their condition.
AstraZeneca's lung cancer treatment recommended for approval in EU
(Sharecast News) - AstraZeneca has announced that its Tagrisso treatment for advanced lung cancer, when combined with chemotherapy, has been recommended for approval by European regulators.
China manufacturing PMI ticks up more than expected - Caixin
(Sharecast News) - Activity in China's manufacturing sector grew in May at the fastest rate in two years, according to data released on Monday.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.